Parallel Advisors, LLC United Therapeutics Corp Transaction History

Parallel Advisors, LLC

$4.18 Billion
Q3 2024

A detailed history of Parallel Advisors, LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,060 shares of UTHR stock, worth $393,079. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,060

Previous 937 13.13%

Holding current value

$393,079

Previous $298,000 27.18%

% of portfolio

0.01%

Previous 0.01%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$311.04 - $363.55 $38,257 - $44,716	123 Added 13.13%	1,060 $379,000
Q2 2024 Aug 08, 2024	BUY	$228.26 - $319.04 $32,869 - $45,941	144 Added 18.16%	937 $298,000
Q1 2024 May 06, 2024	BUY	$210.76 - $249.51 $13,277 - $15,719	63 Added 8.63%	793 $182,000
Q4 2023 Feb 09, 2024	SELL	$214.88 - $256.94 $9,239 - $11,048	-43 Reduced 5.56%	730 $160,000
Q3 2023 May 20, 2024	BUY	$211.82 - $248.24 $12,921 - $15,142	61 Added 8.57%	773 $174,000
Q3 2023 Nov 13, 2023	BUY	$211.82 - $248.24 $12,921 - $15,142	61 Added 8.57%	773 $174,000
Q2 2023 May 20, 2024	BUY	$205.19 - $232.99 $37,344 - $42,404	182 Added 34.34%	712 $157,000
Q2 2023 Aug 04, 2023	BUY	$205.19 - $232.99 $37,344 - $42,404	182 Added 34.34%	712 $157,000
Q1 2023 May 20, 2024	SELL	$212.99 - $276.17 $56,016 - $72,632	-263 Reduced 33.17%	530 $118,000
Q1 2023 Apr 25, 2023	BUY	$212.99 - $276.17 $10,649 - $13,808	50 Added 10.42%	530 $118,000
Q4 2022 Feb 03, 2023	BUY	$205.95 - $280.43 $4,736 - $6,449	23 Added 5.03%	480 $133,000
Q3 2022 Nov 10, 2022	SELL	$203.3 - $244.17 $1,219 - $1,465	-6 Reduced 1.3%	457 $96,000
Q2 2022 Aug 01, 2022	BUY	$174.81 - $241.14 $2,447 - $3,375	14 Added 3.12%	463 $109,000
Q1 2022 Apr 28, 2022	SELL	$166.16 - $213.96 $29,908 - $38,512	-180 Reduced 28.62%	449 $79,000
Q4 2021 Jan 20, 2022	BUY	$184.32 - $216.08 $3,686 - $4,321	20 Added 3.28%	629 $136,000
Q3 2021 Nov 02, 2021	BUY	$179.86 - $214.88 $3,956 - $4,727	22 Added 3.75%	609 $112,000
Q2 2021 Aug 06, 2021	SELL	$170.47 - $211.93 $15,683 - $19,497	-92 Reduced 13.55%	587 $105,000
Q1 2021 Apr 23, 2021	BUY	$153.94 - $174.85 $13,700 - $15,561	89 Added 15.08%	679 $114,000
Q4 2020 Feb 02, 2021	BUY	$101.87 - $151.79 $17,827 - $26,563	175 Added 42.17%	590 $90,000
Q3 2020 Oct 27, 2020	SELL	$99.9 - $121.13 $23,076 - $27,981	-231 Reduced 35.76%	415 $42,000
Q2 2020 Jul 16, 2020	BUY	$92.74 - $125.82 $31,809 - $43,156	343 Added 113.2%	646 $78,000
Q1 2020 Apr 27, 2020	SELL	$79.39 - $115.35 $3,493 - $5,075	-44 Reduced 12.68%	303 $28,000
Q4 2019 Jan 30, 2020	BUY	$78.31 - $95.34 $21,222 - $25,837	271 Added 356.58%	347 $31,000
Q3 2019 Nov 01, 2019	SELL	$74.85 - $85.99 $15,269 - $17,541	-204 Reduced 72.86%	76 $6,000
Q2 2019 Aug 05, 2019	SELL	$76.06 - $120.81 $32,097 - $50,981	-422 Reduced 60.11%	280 $22,000
Q1 2019 May 01, 2019	BUY	$107.15 - $126.84 $7,393 - $8,751	69 Added 10.9%	702 $82,000
Q4 2018 Feb 05, 2019	SELL	$101.4 - $128.73 $55,364 - $70,286	-546 Reduced 46.31%	633 $68,000
Q3 2018 Nov 01, 2018	BUY	$113.81 - $129.46 $40,857 - $46,476	359 Added 43.78%	1,179 $151,000
Q2 2018 Jul 30, 2018	BUY	$101.14 - $118.31 $74,236 - $86,839	734 Added 853.49%	820 $92,000
Q1 2018 May 08, 2018	SELL	$107.21 - $151.94 $15,652 - $22,183	-146 Reduced 62.93%	86 $10,000
Q4 2017 Feb 13, 2018	BUY	$118.58 - $151.28 $1,185 - $1,512	10 Added 4.5%	232 $34,000
Q3 2017 Nov 15, 2017	BUY	$114.6 - $136.81 $25,441 - $30,371	222 New	222 $27,000
Q3 2017 Nov 14, 2017	SELL	$114.6 - $136.81 $25,441 - $30,371	-222 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	222	222 $29,000

Others Institutions Holding UTHR

# of Institutions

679

Shares Held

42.1M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.9B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC United Therapeutics Corp Transaction History